Clinical Trial Update: Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for GSK2879552 in relapsed/refractory small cell lung carcinoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Carcinoma

Drugs mentioned

• GSK2879552

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Small Cell | Phase 1 | Status: TERMINATED | Results posted: 2019-01-23